Impaired TP53 protein function, most frequently reflecting TP53 gene mutation contributes to resistance to cisplatin in ovarian carcinoma cell lines (Herod et al, 1996; Jones et al, 1998; Shimada et al, 2000), and the same could be expected clinically. Here, TP53 is linked to ovarian carcinoma.